126 related articles for article (PubMed ID: 12153156)
21. Evidence for integrin receptor involvement in megakaryocyte-fibroblast interaction: a possible pathomechanism for the evolution of myelofibrosis.
Schmitz B; Thiele J; Otto F; Farahmand P; Henze F; Frimpong S; Wickenhauser C; Fischer R
J Cell Physiol; 1998 Sep; 176(3):445-55. PubMed ID: 9699497
[TBL] [Abstract][Full Text] [Related]
22. Megakaryocyte structure and function.
Cramer EM
Curr Opin Hematol; 1999 Sep; 6(5):354-61. PubMed ID: 10468153
[TBL] [Abstract][Full Text] [Related]
23. Myelofibrosis: a concise review of clinical and pathologic features and treatment.
Smith RE; Chelmowski MK; Szabo EJ
Am J Hematol; 1988 Nov; 29(3):174-80. PubMed ID: 3055953
[TBL] [Abstract][Full Text] [Related]
24. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
25. Rescue of a primary myelofibrosis model by retinoid-antagonist therapy.
Hong SH; Dvorak-Ewell M; Stevens HY; Barish GD; Castro GL; Nofsinger R; Frangos JA; Shoback D; Evans RM
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):18820-5. PubMed ID: 24191050
[TBL] [Abstract][Full Text] [Related]
26. Pathogenesis of myelofibrosis with myeloid metaplasia.
Tefferi A
J Clin Oncol; 2005 Nov; 23(33):8520-30. PubMed ID: 16293880
[TBL] [Abstract][Full Text] [Related]
27. Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1
Verachi P; Gobbo F; Martelli F; Falchi M; di Virgilio A; Sarli G; Wilke C; Bruederle A; Prahallad A; Arciprete F; Zingariello M; Migliaccio AR
Exp Hematol; 2023 Jan; 117():43-61. PubMed ID: 36191885
[TBL] [Abstract][Full Text] [Related]
28. Myelofibrosis: a review of clinical and pathologic features and treatment.
Smith RE; Chelmowski MK; Szabo EJ
Crit Rev Oncol Hematol; 1990; 10(4):305-14. PubMed ID: 2278639
[TBL] [Abstract][Full Text] [Related]
29. Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.
Erba BG; Gruppi C; Corada M; Pisati F; Rosti V; Bartalucci N; Villeval JL; Vannucchi AM; Barosi G; Balduini A; Dejana E
Am J Pathol; 2017 Aug; 187(8):1879-1892. PubMed ID: 28728747
[TBL] [Abstract][Full Text] [Related]
30. Histological evaluation of myeloproliferative neoplasms.
Fujiwara H
J Clin Exp Hematop; 2018; 58(2):45-50. PubMed ID: 29998975
[TBL] [Abstract][Full Text] [Related]
31. Megakaryocytopoiesis in vitro: from the stem cells' perspective.
Cardier JE; Foster DC; Lok S; Jacobsen SE; Murphy MJ
Stem Cells; 1996; 14 Suppl 1():163-72. PubMed ID: 11012217
[TBL] [Abstract][Full Text] [Related]
32. Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis.
Zetterberg E; Verrucci M; Martelli F; Zingariello M; Sancillo L; D'Amore E; Rana RA; Migliaccio AR
Platelets; 2014; 25(7):539-47. PubMed ID: 24176039
[TBL] [Abstract][Full Text] [Related]
33. Ultrastructure of bone marrow tissue in so-called primary (idiopathic) myelofibrosis-osteomyelosclerosis (agnogenic myeloid metaplasia). I. Abnormalities of megakaryopoiesis and thrombocytes.
Thiele J; Kuemmel T; Sander C; Fischer R
J Submicrosc Cytol Pathol; 1991 Jan; 23(1):93-107. PubMed ID: 2036630
[TBL] [Abstract][Full Text] [Related]
34. Emperipolesis of hematopoietic cells within megakaryocytes in bone marrow of the rat.
Lee KP
Vet Pathol; 1989 Nov; 26(6):473-8. PubMed ID: 2603328
[TBL] [Abstract][Full Text] [Related]
35. [Comparative study on bone marrow megakaryocytes in children with thrombocytopenic purpura, aplastic anemia and myelodysplastic syndrome].
Hu T; Shi XD; Feng YL; Liu R; Li JH; Chen J; Wang TY
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):183-7. PubMed ID: 15833188
[TBL] [Abstract][Full Text] [Related]
36. Mixed myelodysplastic syndrome and myeloproliferative disorder with bone marrow and pulmonary fibrosis: the role of megakaryocytes.
Rosenstingl S; Brouland JP; Zini JM; Tobelem G; Dupuy E
Acta Haematol; 2003; 109(3):145-9. PubMed ID: 12714825
[TBL] [Abstract][Full Text] [Related]
37. Characterization of an acute micromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis.
Reilly JT; Barnett D; Dolan G; Forrest P; Eastham J; Smith A
Br J Haematol; 1993 Jan; 83(1):58-62. PubMed ID: 8435338
[TBL] [Abstract][Full Text] [Related]
38. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of myelofibrosis with myeloid metaplasia: lessons from mouse models of the disease.
Vannucchi AM; Migliaccio AR; Paoletti F; Chagraoui H; Wendling F
Semin Oncol; 2005 Aug; 32(4):365-72. PubMed ID: 16202682
[TBL] [Abstract][Full Text] [Related]
40. Impaired GATA-1 expression and myelofibrosis in an animal model.
Vannucchi AM; Bianchi L; Paoletti F; Di Giacomo V; Migliaccio G; Migliaccio AR
Pathol Biol (Paris); 2004 Jun; 52(5):275-9. PubMed ID: 15217713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
